Mehdinejad Masoud, Sobhan Mohammad Reza, Mazaheri Mahta, Zare Shehneh Masoud, Neamatzadeh Hossein, Kalantar Seyed Mahdi
Department of Orthopedics, Afshar Hospital, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Email:
Asian Pac J Cancer Prev. 2017 May 1;18(5):1315-1321. doi: 10.22034/APJCP.2017.18.5.1315.
Background: To date, only a few studies have investigated associations between ERCC2, NBN, and RAD51 variants and risk of developing osteosarcoma. In this systematic review and meta-analysis, we focused on clarifying links. Materials and Methods: We systematically searched PubMed, Google Scholar, and ISI web of knowledge databases to identify relevant studies. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to calculate the strength of associations with fixed effect models. Results: No statistical evidence of association was found between ERCC2 rs13181 (G vs. T: OR= 1.224, 95% CI: 0.970-1.545, p= 0.088; GT vs. TT: OR= 1.135, 95% CI: 0.830-1.552, p= 0.428; GG vs. TT: OR= 1.247, 95% CI: 0.738-2.108, p= 0.409; GG+GT vs. TT: OR= 1.174, 95% CI: 0.929-1.484, p= 0.179; GG vs. GT+TT: OR= 1.476, 95% CI: 0.886-2.460, p= 0.135), ERCC2 rs1799793 (GA+AA vs. GG: OR= 1.279, 95% CI: 0.912-1.793, p= 0.154), NBN rs709816 (OR= 1.047, 95% CI: 0.763-1.437, p= 0.775), NBN rs1805794 (OR= 1.126, 95% CI: 0.789-1.608, p= 0.513), RAD51 rs1801320 (OR= 0.977, 95% CI: 0.675-1.416, p= 0.904), RAD51 rs1801321 (TT+GT vs. GG: OR= 1.167, 95% CI: 0.848-1.604, p= 0.343), RAD51 rs12593359 (GG+GT vs. TT: OR= 0.761, 95% CI: 0.759-1.470, p= 0.744) polymorphisms and osteosarcomas. The lack of the original data limited our further evaluation of the adjusted ORs concerning age and gender; however, the previous individual studies results indicated the age- and gender-specific effects of two ERCC2 rs1799793 and NBN rs1805794 variants on osteosarcoma risk. Conclusion: The results suggested a lack of association between the ERCC2 (rs13181 and rs1799793), NBN (rs709816 and rs1805794), and RAD51 (rs1801320, rs1801321, and rs12593359) variants with osteosarcoma risk. Further comprehensive and well-designed studies are required to assess the role for ERCC2, NBN, RAD51 variants in osteosarcoma development more adequately.
迄今为止,仅有少数研究调查了ERCC2、NBN和RAD51基因变异与骨肉瘤发生风险之间的关联。在本系统评价和荟萃分析中,我们着重于阐明其间的联系。
我们系统检索了PubMed、谷歌学术和ISI知识网络数据库以识别相关研究。采用比值比(OR)及95%置信区间(CI),通过固定效应模型计算关联强度。
未发现ERCC2基因rs13181位点(G与T比较:OR = 1.224,95%CI:0.970 - 1.545,p = 0.088;GT与TT比较:OR = 1.135,95%CI:0.830 - 1.552,p = 0.428;GG与TT比较:OR = 1.247,95%CI:0.738 - 2.108,p = 0.409;GG + GT与TT比较:OR = 1.174,95%CI:0.929 - 1.484,p = 0.179;GG与GT + TT比较:OR = 1.476,95%CI:0.886 - 2.460,p = 0.135)、ERCC2基因rs1799793位点(GA + AA与GG比较:OR = 1.279,95%CI:0.912 - 1.793,p = 0.154)、NBN基因rs709816位点(OR = 1.047,95%CI:0.763 - 1.437,p = 0.775)、NBN基因rs1805794位点(OR = 1.126,95%CI:0.789 - 1.608,p = 0.513)、RAD51基因rs1801320位点(OR = 0.977,95%CI:0.675 - 1.416,p = 0.904)、RAD51基因rs1801321位点(TT + GT与GG比较:OR = 1.167,95%CI:0.848 - 1.604,p = 0.343)、RAD51基因rs12593359位点(GG + GT与TT比较:OR = 0.761,95%CI:0.759 - 1.470,p = 0.744)多态性与骨肉瘤之间存在统计学关联证据。原始数据的缺失限制了我们对年龄和性别校正OR值的进一步评估;然而,既往的个体研究结果显示ERCC2基因rs1799793和NBN基因rs1805794两个位点的变异对骨肉瘤风险存在年龄和性别特异性影响。
结果提示ERCC2(rs13181和rs1799793)、NBN(rs709816和rs1805794)以及RAD51(rs1801320、rs1801321和rs12593359)基因变异与骨肉瘤风险之间缺乏关联。需要进一步开展更全面且设计良好的研究,以更充分地评估ERCC2、NBN、RAD51基因变异在骨肉瘤发生发展中的作用。